Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Korea United PharmXKRX:033270 -1.38%90 Gross Margin % is 55.48% as of Jun. 2026, which is 2% below its 10-year median of 56.79. GuruFocus rates XKRX:033270 with a GF Score™ of 90/100 and a GF Value™ of ₩20,354.74 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 938 Drug Manufacturers companies, Korea United Pharm ranks better than 61.51% on this metric.
The historical rank and industry rank for Korea United Pharm's Gross Margin % or its related term are showing as below:
XKRX:033270'
s Gross Margin % Range Over the Past 10 Years
Min: 54.74 Med: 56.79 Max: 59.21
Current: 55.1
During the past 13 years, the highestGross Margin % of Korea United Pharm was 59.21%. The lowest was 54.74%. And the median was 56.79%.
XKRX:033270's Gross Margin % is ranked better than 61.51% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.47
vs XKRX:033270: 55.10
Korea United Pharm had a gross margin of 55.48% for the quarter that ended in Jun. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Korea United Pharm was -0.30% per year.
Korea United Pharm (XKRX:033270) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Korea United Pharm had a gross margin of 55.48% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Korea United Pharm Gross Margin % Related Terms
Korea United Pharm Gross Margin % Historical Data
* Premium members only.
The historical data trend for Korea United Pharm's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Korea United Pharm's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Korea United Pharm Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Korea United Pharm's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Korea United Pharm's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Korea United Pharm (XKRX:033270) has a Gross Margin % of 55.48% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Korea United Pharm and its competitors. This is near median its historical median of 56.79. Over the past decade, Korea United Pharm's Gross Margin % has ranged from 54.74 to 59.21. According to the industry distribution chart, Korea United Pharm ranks #361 out of 938 companies in the Drug Manufacturers industry, placing it in the top 38.5%.
Is Korea United Pharm's Gross Margin % too high?
Korea United Pharm's current Gross Margin % of 55.48% is near median its 10-year median of 56.79. Over the past 10 years, this metric has ranged from a low of 54.74 to a high of 59.21. The Drug Manufacturers industry median Gross Margin % is 48.47. Korea United Pharm's value of 55.48% is 14.5% above this industry median. Based on the distribution chart, Korea United Pharm ranks #361 out of 938 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Korea United Pharm has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Korea United Pharm's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Korea United Pharm ranks #361 out of 938 companies for Gross Margin %. This puts Korea United Pharm in the upper half of its industry. The industry median Gross Margin % is 48.47. Korea United Pharm's value of 55.48% is 14.5% above this benchmark. Historically, Korea United Pharm's own Gross Margin % has ranged from 54.74 to 59.21 over the past decade. While the company's 10-year median is 56.79 vs. the industry median of 48.47, Korea United Pharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.47, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Korea United Pharm's current Gross Margin % of 55.48% is 14.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Korea United Pharm and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Korea United Pharm's current Gross Margin % is 55.48%, which is near median its own 10-year median of 56.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Korea United Pharm stock overvalued right now?
Based on GuruFocus' analysis, Korea United Pharm (XKRX:033270) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩20,354.74, compared to a current price of ₩17,910.00 — trading 12% below its estimated fair value. The current Gross Margin % is 55.48%, which is near median its 10-year median of 56.79 and 14.5% above the Drug Manufacturers industry median of 48.47. Korea United Pharm's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Korea United Pharm (XKRX:033270), the current Gross Margin % is 55.48% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Korea United Pharm (XKRX:033270) Overvalued in 2026?
Based on GuruFocus' analysis, Korea United Pharm stock appears to be undervalued.
The current stock price of ₩17,910.00 is trading 12% below its estimated GF Value™ of ₩20,354.74.
GuruFocus considers Korea United Pharm to be Modestly Undervalued.
Key valuation signals for XKRX:033270:
Gross Margin %: 55.48% (near median its 10-year median of 56.79)
GF Value™: ₩20,354.74 vs. price of ₩17,910.00 (12% below fair value)
Industry Position: 14.5% above the Drug Manufacturers median (#361 of 938)
No single metric tells the full story. See the XKRX:033270 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Korea United Pharm Inc is a South Korea based company engages in the manufacture and distribution of pharmaceuticals and healthcare products. It offers incrementally modified drug, anti-cancer, prescription, and OTC products.
90GF Score
Get the complete analysis for XKRX:033270
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:033270 has been successfully added to your 
